By Stephen Nakrosis


Eli Lilly and Co. on Tuesday said it entered a Joint Procurement Agreement with the European Commission to supply bamlanivimab and etesevimab for confirmed cases of Covid-19.

The pharmaceutical company said the deal will see it supply up to 220,000 doses to treat confirmed cases of Covid-19 in certain patients aged 12 and older.

The deal allows participating nations in the European Union and European Economic Area to buy the products directly from Lilly "following national approval for emergency use, or marketing authorization at the EU level," the company said.

Alfonso Zulueta, senior vice president and president, Lilly International, said, "Bamlanivimab and etesevimab have played an important role in the fight against Covid-19, helping hundreds of thousands of patients globally." He added "Lilly is pleased to have reached this agreement with the European Commission which opens the door for many European countries to access this life-saving treatment option for patients with Covid-19."

Bamlanivimab administered with etesevimab is available under emergency pathways in 15 countries around the world to treat Covid-19, Lilly said.


Write to Stephen Nakrosis at


(END) Dow Jones Newswires

September 21, 2021 14:10 ET (18:10 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Eli Lilly Charts.